DrugBiological
Sotigalimab clinical trials
Also written APX005M.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
Other names
Studies by the year they started
12 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 7
Apexigen America, Inc. (4) · M.D. Anderson Cancer Center (2) · Pediatric Brain Tumor Consortium (1) · Yale University (1) · Alexander Z. Wei, MD (1) · Parker Institute for Cancer Immunotherapy (1) · BioNTech US Inc. (1) · Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1)
Often tested with
Tested in the same studies.
Nivolumab (3) · Pembrolizumab (2) · Ipilimumab (2) · Doxorubicin (1) · Personalized Peptide Cancer Vaccine NEO-PV-01 (1)
Studies
Open first, then newest update. How each study uses sotigalimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02600949Written as Sotigalimab
- Phase I Study of APX005M in Pediatric Central Nervous System TumorsCompletedPhase 1Pediatric Brain Tumor ConsortiumNCT03389802Written as APX005M treatment for recurrent or refractory primary malignant CNS tumor patients
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)CompletedPhase 1Yale UniversityNCT04495257Written as APX005M
- APX005M and Doxorubicin in Advanced SarcomaCompletedPhase 2Alexander Z. Wei, MDNCT03719430Written as APX005M
- APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02706353Written as APX005M
- APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction CancersCompletedPhase 2Apexigen America, Inc.NCT03165994Written as APX005M
- A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic MelanomaTerminatedPhase 2Apexigen America, Inc.NCT04337931Written as sotigalimab
- CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabCompletedPhase 1/2Apexigen America, Inc.NCT03123783Written as APX005M
- Study of the CD40 Agonistic Monoclonal Antibody APX005MCompletedPhase 1Apexigen America, Inc.NCT02482168Written as APX005M
- APX005M in Patients With Recurrent Ovarian CancerWithdrawnPhase 2Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT05201001Written as APX005M
- Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedPhase 1/2Parker Institute for Cancer ImmunotherapyNCT03214250Written as APX005M
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedPhase 1BioNTech US Inc.NCT03597282Written as APX005M
Given in every arm · 2 — sotigalimab is usual care beside what is tested
Codes
What other systems call sotigalimab · ClinicalTrials.gg INT001962
- MeSH (NLM) C000723517sotigalimabOne source ClinicalTrials.gov
- UNII (FDA) JEA93WJ5DGSOTIGALIMABOne source FDA
- NCI Thesaurus C123734SotigalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723517 | sotigalimab | One source ClinicalTrials.gov |
| UNII (FDA) | JEA93WJ5DG | SOTIGALIMAB | One source FDA |
| NCI Thesaurus | C123734 | Sotigalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.